Innovating Safer Solutions for the Treatment of Metastatic Breast Cancer
Founded in 2015 as an R&D, pre-revenue startup, TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients.
TTC Oncology has a license from the University of Illinois at Chicago covering the therapy associated with modulation and mimicry of estrogen actions.
TTC Oncology completed a Phase I trial of their proprietary drug at four clinical sites under the guidance of breast cancer oncologists and consultants with extensive experience in pharma and biotech.
TTC Oncology has $6.2 million invested today. With drug safety established in the Phase I study, TTC Oncology is seeking investment to complete international pivotal Phase II clinical trials that are in preparation.